Next Generation Oncology Treatments

/
Next Generation Oncology Treatments


Next Generation Oncology Treatments

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

Immune Oncology
11:50-11:55 Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

11:55-12:35 Prof. Jeffrey A. Sosman, MD, Director, Melanoma Program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

12:35-12:50 Julian Adams, Chairman & CEO, Gamida Cell

12:50-13:05 Yaron Pereg, CEO, Kahr Medical: “KAHR Medical Dual Signaling Proteins (DSP) Platform – the Next Generation of Cancer Immunotherapy”

13:05-13:20 Tehila Ben Moshe, CEO,Biond Biologics: “Biond Biologics- Translating Great Science to Innovative Bio Therapies”

13:20-13:35 Aviv Boim, CEO, Tikcro Technologies: “Immune Oncology – Selective Blocking Antibodies”

13:35-13:50 Irit Carmi-Levy, Drug Development Manager, BiolineRX: “AGI-134: Small Molecule Inducing Hyper-acute, Multi-arm Immune Response Targeting Tumor-specific Neoantigens”

13:50-15:20 Lunch Break

Oncology
15:20-15:40 Phil L’Huillier, PhD, MBA,  Head, European Innovation Hub, MSD: “MSD Immuno-Oncology Overview”

15:40-16:00 Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Translating mRNA Vaccines and Therapeutics into IO Agents”

16:00-16:15 Dror Harats, MD, CEO Vascular Therapeutics: “MOSPD2: A Novel Target for Antibody-Mediated Killing of Tumor Cells”

16:15-16:30 Roni Mamluk, PhD, CEO, Ayala Pharmaceuticals: “Ayala – A New Clinical Stage Precision Oncology Company”

16:30-16:45 Ori Kalid, Co-Founder & CEO, Pi Therapeutics: “Novel First-in-class Inhibitors of Protein Degradation – an Unfolding Story”

16:45-17:00 Gil Hakim, President, IL Operations, UroGen Pharma: “Transforming Local Therapies in Urology”

17:00-17:45 Roundtable Discussion: Precision Medicine in Oncology
Panelists:
Prof. Jeffrey A. Sosman, MD, Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Phil L’Huillier, PhD, MBA,  Head, European Innovation Hub, MSD
Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics
Roni Mamluk, PhD, CEO, Ayala Pharmaceuticals
Dror Harats, MD, CEO Vascular Therapeutic

By | 2018-05-10T13:57:15+00:00 February 19th, 2018|Comments Off on
Next Generation Oncology Treatments

About the Author: